The management of chronic heart failure in the setting of chronic kidney disease is an important topic, particularly for pharmacists, because the cornerstone for the treatment of heart failure is pharmacotherapy. Heart failure also remains the leading discharge diagnosis among patients greater than 65, and anywhere from 40 to 45% of individuals who have chronic heart failure also have some form of chronic kidney disease. In this module, we will cover the importance of guideline-directed medical therapy (GDMT), pharmacologic diuresis, and altering GDTM for those with CKD.
Robert Page, PharmD, MSPH, BCPS, BCGP, FAHA, FHFSA, FCCP, FASHP
Professor, University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences
Dr. Robert Page is currently a Professor in the Departments of Clinical Pharmacy, Medicine, and Physical Medicine at the University of Colorado Schools of Pharmacy and Medicine. As the clinical pharmacy specialist for the Division of Cardiology, Section of Advanced Heart Failure/Transplant, he has managed acute and chronic heart failure within both the inpatient and outpatient setting for over 25 years.
Disclosures
The following planners and presenters have disclosed a financial relationship with an ineligible company:
- Wendy St Peter, FCCP, FASN, FNKF - Consultant [GSK]
There are no conflicts of interest or financial relationships with an ineligible company that have been disclosed by the rest of the planners and presenters of this learning activity.
All relevant financial relationships have been mitigated.
